MeMed Secures $93M Financing To Commercialize Diagnostics Platform
The company will use the money to fund its US commercialization strategy and continue to develop its host response-based product pipeline.
You may also be interested in...
Minute Insight: MeMed Announces Viral/Bacterial Infection Differentiation Results, Commercial Partnership
DiaSorin will distribute MeMed BV, a rapid point-of-care test that can differentiate bacterial and viral infections, under a new commercial agreement.
Kfir Oved, co-founder and CTO of MeMed, talked to Medtech Insight about diagnostic testing that can differentiate bacterial and viral infections to fight antimicrobial resistance.
Approved in Europe and just given the US green light, MeMed is making waves in the fight against antimicrobial resistance using advanced "host response" technology. Its CEO talks to In Vivo about strategy, commercialization and earning the right to fantasize.